Scientific Publications
A robust body of evidence highlights the potential of psychedelics to be transformative treatments for mental health conditions
Mebufotenin
- Rucker J, Butler M, Hambleton S, et al. Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study. Headache. (2024)
- Rucker JJ, Roberts C, Seynaeve M, et al. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. Journal of Psychopharmacology. (2024)
- Ermakova AO, Dunbar F, Rucker J, Johnson MW. A narrative synthesis of research with 5-MeO-DMT. Journal of Psychopharmacology. (2021)
DMT
- VLS-01: Society of Biological Psychiatry (SOBP) 2025 Poster
- Szabo et al., The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells (2016)
- Argento et al., Exploring ayahuasca‐assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada (2019)
- Palhano-Fontes et al., Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression (2019)
- Timmermann et al., Neural correlates of the DMT experience assessed with multivariate EEG (2019)
- Pallavicini et al., Neural and subjective effects of inhaled DMT in natural settings (2020)
- Pasquini et al., Subacute effects of the psychedelic ayahuasca on the salience and default mode networks (2020)
MDMA
- MAPS, MAPS – MDMA Investigator’s Brochure (10th Edition) (2018)
- Rudnick & Wall, The molecular mechanism of “ecstasy” [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release (1992)
- Carhart-Harris et al., The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity (2015)
- Mitchell et al., MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (2021)
- Mitchell et al., MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (2023)
Discovery
- Robertson, et al., Identification of Lead 5-HT2A Receptor Agonists for use in Treatment Resistant Depression with Non-hallucinogenic Potential and Low Valvulopathy Liability
- Bowen, et al., Discovery of novel 5-HT2A receptor agonists with non-hallucinogenic potential and translational antidepressant drug-like profiles
- Bowen, et al., Novel 5-HT2A receptor agonists exhibit translational antidepressant and psychedelic drug-like profiles in a model of treatment-resistant depression (2023)
- Bowen, et al., Discovery of novel 5-HT2A receptor agonists with psychedelic drug-like in vitro and in vivo pharmacological activity and therapeutic potential for treatment-resistant depression (2023)
- Bowen, et al., Discovery of novel 5-HT2A receptor modulators for the treatment of mood disorders
Learn more
Pipeline
